These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 4602407)

  • 21. Secondary dapsone-resistant leprosy in Shanghai Municipality.
    Ji BH; Chen JK; Zhang JL; Hou YH; Ni GX; Zhang RB
    Lepr Rev; 1983 Sep; 54(3):197-202. PubMed ID: 6355724
    [No Abstract]   [Full Text] [Related]  

  • 22. [2 cases of paucibacillary leprosy resistant to dapsone].
    Janssens L
    Acta Leprol; 1982; (86-87):181-3. PubMed ID: 6815986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Resistance of Mycobacterium leprae to sulfones (DDS) and rifampicin in recurring lepromatous leprosy in Martinique and Guadeloupe since February 1980].
    Guelpa-Lauras CC; Constant-Desportes M; Millan J; Grosset J
    Acta Leprol; 1982; (86-87):77-80. PubMed ID: 6816000
    [No Abstract]   [Full Text] [Related]  

  • 24. [Drug resistance of Mycobacterium leprae].
    Pattyn SR
    Acta Leprol; 1986; 4(3):279-87. PubMed ID: 3551466
    [No Abstract]   [Full Text] [Related]  

  • 25. [Antibacterial chemotherapy in leprosy: principles, objectives and recommendations].
    Sansarricq H
    Acta Leprol; 1986; 4(3):355-62. PubMed ID: 3551474
    [No Abstract]   [Full Text] [Related]  

  • 26. The effect of rifampicin and dapsone on experimental Mycobacterium leprae infections: minimum inhibitory concentrations and bactericidal action.
    Holmes IB; Hilson GR
    J Med Microbiol; 1972 May; 5(2):251-61. PubMed ID: 4555734
    [No Abstract]   [Full Text] [Related]  

  • 27. [Clinical and paraclinical aspects of secondary drug resistance to 4-4' diaminodiphenylsulfone in a population of leprosy patients in Bamako, Republic of Mali].
    Baquillon G; Ferracci C; Diallo J; Saint-Andreé P; Pattyn SR
    Acta Leprol; 1981; 85():40-52. PubMed ID: 6805234
    [No Abstract]   [Full Text] [Related]  

  • 28. [Sulfone-resistance of Mycobacterium leprae--monotherapy with diaminodiphenylsulfone--the value of triple-drug combinations].
    Floch HA
    Int J Lepr Other Mycobact Dis; 1986 Mar; 54(1):122-5. PubMed ID: 3519797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dapsone-resistant Mycobacterium leprae in a patient receiving dapsone in low doses.
    Browne SG
    Int J Lepr Other Mycobact Dis; 1969; 37(3):296-301. PubMed ID: 4906048
    [No Abstract]   [Full Text] [Related]  

  • 30. Survey of primary dapsone-resistant leprosy.
    Wang HY; Li WZ; Yang LH; Huang HS; Lu WQ; Yu LC
    Proc Chin Acad Med Sci Peking Union Med Coll; 1986; 1(3):173-5. PubMed ID: 3321049
    [No Abstract]   [Full Text] [Related]  

  • 31. [Prevalence of dapsone-resistant leprosy in Burundi. Temporary results].
    Bourland J; Van Loo L; Pattyn SR
    Acta Leprol; 1982; (86-87):29-33. PubMed ID: 6815995
    [No Abstract]   [Full Text] [Related]  

  • 32. Characteristics of the multiplication of dapsone-resistant strains of Mycobacterium leprae in mice. Subcommittee on Clinical Trials of the C hemotherapy of Leprosy (THELEP) Scientific Working Group of UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases.
    Lepr Rev; 1988 Mar; 59(1):5-10. PubMed ID: 3294541
    [No Abstract]   [Full Text] [Related]  

  • 33. Controlled long-term therapy of leprosy with B663 (lamprene, clofazimine) compared with DDS.
    Tolentino JG; Rodriquez JN; Abalos RM
    Int J Lepr Other Mycobact Dis; 1974; 42(4):416-418. PubMed ID: 4617720
    [No Abstract]   [Full Text] [Related]  

  • 34. Dormancy, drug resistance or dependency; some thoughts to ponder.
    Shetty VP; Mistry NF; Uplekar MW; Antia NH; Pai VV; Ganapati R
    Int J Lepr Other Mycobact Dis; 1996 Dec; 64(4):455-7. PubMed ID: 9030116
    [No Abstract]   [Full Text] [Related]  

  • 35. [Resistance of Mycobacterium leprae to dapsone and rifampicin: apropos of a survey carried out in the Cape Verde region (Senegal)].
    Grosset J; Guelpa-Lauras CC; Millan J; Bodian M; Perani E
    Med Trop (Mars); 1987; 47(2):171-5. PubMed ID: 3306248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The sensitivity to Dapsone (DDS) of Mycobacterium leprae from patients with and without previous treatment.
    Shepard CC; Levy L; Fasal P
    Am J Trop Med Hyg; 1969 Mar; 18(2):258-63. PubMed ID: 4888029
    [No Abstract]   [Full Text] [Related]  

  • 37. Dapsone resistance in patients attending Central Leprosy Teaching and Research Institute, Chengalpattu (South India).
    Bhatia VN; Balakrishnan S; Seshadri PS; Neelan PN; Roy RG
    Indian J Lepr; 1984; 56(3):587-94. PubMed ID: 6396340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The problem of dapsone-resistant leprosy.
    Pearson JM
    Int J Lepr Other Mycobact Dis; 1981 Dec; 49(4):417-20. PubMed ID: 7042605
    [No Abstract]   [Full Text] [Related]  

  • 39. Screening of drugs for activity against Mycobacterium leprae.
    Baohong J; Matsuo Y; Colston MJ
    Int J Lepr Other Mycobact Dis; 1987 Dec; 55(4 Suppl):836-42. PubMed ID: 3325576
    [No Abstract]   [Full Text] [Related]  

  • 40. Concepts behind the development of multiple drug therapy regimens in leprosy.
    Waters MF
    Lepr Rev; 1986 Dec; 57 Suppl 1():61-7. PubMed ID: 3295437
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.